CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

T 细胞增殖调控因子在实体瘤治疗与预后预测中的综述

英文原题：Review of T cell proliferation regulatory factors in treatment and prognostic prediction for solid tumors.

查看英文原题

Review of T cell proliferation regulatory factors in treatment and prognostic prediction for solid tumors.

PubMed 2023/10/29（内容时间） Heliyon

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

技术：CAR-T实体瘤地区：中国
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

中文摘要

T细胞增殖调节因子（Tcpr）是促进T细胞功能的正向调节因子，对开发增强T细胞功能的疗法作出了重要贡献。CAR（嵌合抗原受体）T细胞疗法是一种靶向肿瘤细胞并增强免疫杀伤能力的过继细胞转移疗法，已在血液系统肿瘤治疗中取得显著进展。然而，CAR-T 在实体瘤治疗中的应用仍然有限。因此，本综述聚焦Tcpr在实体瘤治疗和预后预测中的研究进展。我们总结靶向不同Tcpr的潜在策略，这些策略可增强T细胞增殖和活化、抑制癌症进展，从而提高CAR-T 的抗肿瘤活性和持久性。总之，我们提出通过表达不同Tcpr增强CAR-T 细胞的方法，有望推动新一代细胞疗法的开发。

展开英文摘要原文

T cell proliferation regulators (Tcprs), which are positive regulators that promote T cell function, have made great contributions to the development of therapies to improve T cell function. CAR (chimeric antigen receptor) -T cell therapy, a type of adoptive cell transfer therapy that targets tumor cells and enhances immune lethality, has led to significant progress in the treatment of hematologic tumors.

However, the applications of CAR-T in solid tumor treatment remain limited.

Therefore, in this review, we focus on the development of Tcprs for solid tumor therapy and prognostic prediction.

We summarize potential strategies for targeting different Tcprs to enhance T cell proliferation and activation and inhibition of cancer progression, thereby improving the antitumor activity and persistence of CAR-T. In summary, we propose means of enhancing CAR-T cells by expressing different Tcprs, which may lead to the development of a new generation of cell therapies.

论文信息

作者
Li J、Ma S、Pei H、Jiang J、Zou Q、Lv Z
单位
Student Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China.China
文献类型
综述
期刊
Heliyon2023 Nov
原文标识
PubMed 37954355　·　DOI 10.1016/j.heliyon.2023.e21329

在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →